Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
Trends Pharmacol Sci. 2012 Oct;33(10):522-30. doi: 10.1016/j.tips.2012.06.007. Epub 2012 Jul 12.
The transcription factors nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are critical regulators of stress responses, immunity, inflammation and cancer. A large variety of cellular stimuli utilize these signaling pathways through a common upstream kinase transforming growth factor-β-activated kinase 1 (TAK1). TAK1 was originally identified as a mitogen-activated kinase kinase kinase (MAP3K) activated by transforming growth factor-β (TGF-β); however, it has been characterized as a key regulator in inflammatory and immune signaling pathways. In addition, microbial proteins and components of host cell signaling scramble for the TAK1 complex in innate immunity. This review highlights the recent advances in the activation mechanisms and physiological functions of TAK1. Research targeting TAK1 raises the potential for new therapeutic options for inflammatory disorders, including cancer.
转录因子核因子-κB(NF-κB)和激活蛋白-1(AP-1)是应激反应、免疫、炎症和癌症的关键调节剂。大量的细胞刺激物通过共同的上游激酶转化生长因子-β激活激酶 1(TAK1)利用这些信号通路。TAK1 最初被鉴定为丝裂原激活蛋白激酶激酶激酶(MAP3K),由转化生长因子-β(TGF-β)激活;然而,它已被表征为炎症和免疫信号通路中的关键调节剂。此外,微生物蛋白和宿主细胞信号成分在先天免疫中争夺 TAK1 复合物。本综述强调了 TAK1 的激活机制和生理功能的最新进展。针对 TAK1 的研究为炎症性疾病(包括癌症)的新治疗选择提供了潜力。